Bor-Show Tzang

Prof. Bor-Show Tzang

Department of Biochemistry and Institute of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
HLHsiao-Sui Lo
Hsiao-Sui Lo
CYChien-Ming Yang
Chien-Ming Yang
HLHelen G. Lo
Helen G. Lo
CLChien-Ying Lee
Chien-Ying Lee
HTHua Ting
Hua Ting
BTBor-Show Tzang
Bor-Show Tzang
The prevalence of insomnia is very high in our society. Although pharmacological treatment of insomnia is available, most hypnotics have been shown to alter sleep architecture and have many adverse effects. Gabapentin was originally designed for antiepileptic therapy; however, some studies reported that its use increases slow-wave sleep in healthy volunteers or patients. Our goal was to evaluate the benefits of gabapentin in the treatment of primary insomnia in patients. Eighteen patients with primary insomnia participated in the study. They received gabapentin treatment for at least 4 weeks. All patients received polysomnography, a biochemical blood test, and neuropsychological tests before and after the treatment period. All measures were analyzed with Student t test to examine the treatment effects of gabapentin, except that the measures of heart rate variability were analyzed with analysis of variance. Polysomnographic study revealed increased sleep efficiency and slow-wave sleep, decreased wake after sleep onset, and spontaneous arousal index after gabapentin treatment. The biochemical blood test revealed decreased prolactin levels in the morning after treatment. Electroencephalographic power spectral analysis showed increased delta-2 and theta power in sleep stage 1 and decreased sigma activity power in sleep stages N2 and N3 after gabapentin treatment. Heart rate variability analyses also showed a significant increase in normalized high frequency percentage in sleep stages N2 and N3 and low frequency-high frequency ratio in sleep stage N2 after treatment. In addition, neuropsychological tests revealed the elevation of visual motor processing speed after gabapentin treatment. Gabapentin enhances slow-wave sleep in patients with primary insomnia. It also improves sleep quality by elevating sleep efficiency and decreasing spontaneous arousal. The results suggest that gabapentin may be beneficial in the treatment of primary insomnia.

1 April 2006 in Clinica Chimica Acta
Verified
Journal Article
Closed access
EHErh-Jung Huang
Erh-Jung Huang
WKWei-Wen Kuo
Wei-Wen Kuo
YCYuh-Jyuan Chen
Yuh-Jyuan Chen
TCTer-Hsin Chen
Ter-Hsin Chen
MCMu-Hsin Chang
Mu-Hsin Chang
Shin-Da LeeShin-Da Lee
Shin-Da Lee

14 February 2008 in Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
CCChun-Hsien Chu
Chun-Hsien Chu
BTBor-Show Tzang
Bor-Show Tzang
LCLi-Mien Chen
Li-Mien Chen
Chia-Hua KuoChia-Hua Kuo
Chia-Hua Kuo
YCYi-Chang Cheng
Yi-Chang Cheng
CHChih-Yang Huang
Chih-Yang Huang
The role played by IGF-II in signal transduction through the IGF-II/mannose-6-phosphate receptor (IGF2R) in heart tissue has been poorly understood. In our previous studies, we detected an increased expression of IGF-II and IGF2R in cardiomyocytes that had undergone pathological hypertrophy. We hypothesized that after binding with IGF-II, IGF2R may trigger intracellular signaling cascades involved in the progression of pathologically cardiac hypertrophy. In this study, we used immunohistochemical analysis of the human cardiovascular tissue array to detect expression of IGF2R. In our study of H9c2 cardiomyoblast cell cultures, we used the rhodamine phalloidin staining to measure the cell hypertrophy and western blot to measure the expression of cardiac hypertrophy markers atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in cells treated with IGF-II. We found that a significant association between IGF2R overexpression and myocardial infarction. The treatment of H9c2 cardiomyoblast cells with IGF-II not only induced cell hypertrophy but also increased the protein level of ANP and BNP. Using Leu27IGF-II, an analog of IGF-II which interacts selectively with the IGF2R, to specifically activate IGF2R signaling cascades, we found that binding of Leu27IGF-II to IGF2R led to an increase in the phosphorylation of protein Kinase C (PKC)-α and calcium/calmodulin-dependent protein kinase II (CaMKII) in a Gαq-dependent manner. By the inhibition of PKC-α/CaMKII activity, we found that IGF-II and Leu27IGF-II-induced cell hypertrophy and upregulation of ANP and BNP were significantly suppressed. Taken together, this study provides a new insight into the effects of the IGF2R and its downstream signaling in cardiac hypertrophy. The suppression of IGF2R signaling pathways may be a good strategy to prevent the progression of pathological hypertrophy.

28 November 2025 in eClinicalMedicine
Verified
Journal Article
Open access
CTChih-Chen Tzang
Chih-Chen Tzang
PWPei-Hsun Wu
Pei-Hsun Wu
CLChiao-An Luo
Chiao-An Luo
ZCZi-Ting Chen
Zi-Ting Chen
YLYi-Ting Lee
Yi-Ting Lee
THTSAI-CHING HSU
TSAI-CHING HSU
To quantify the extent of metabolic and cardiovascular rebound following the discontinuation of GLP-1 receptor agonist (GLP-1RA) therapy in adults with obesity, type 2 diabetes, or type 1 diabetes, and identify potential modifiers of these outcomes. We conducted a systematic review and meta-analysis of randomized controlled trials including adults and adolescents treated with GLP-1RAs, followed by a post-discontinuation follow-up of at least 12 weeks. Databases searched included MEDLINE, Embase, Cochrane CENTRAL, Web of Science, and ClinicalTrials.gov, with no language restrictions, and published up to October 17, 2025. We assessed changes in anthropometric, glycemic, cardiovascular, and lipid parameters between the end of treatment and the post-cessation period. Random-effects models were used to calculate pooled mean differences. The risk of bias and certainty of evidence were evaluated using the Cochrane ROB 2.0 and GRADE frameworks. The study was registered with PROSPERO under CRD42025646185. Eighteen RCTs (3771 participants) were included. Among individuals with obesity, discontinuation of GLP-1RA resulted in significant metabolic rebound, characterized by a body weight gain of 5.63 kg (95% CI: 3.52–7.73, I2 = 99.57%, moderate) and an increase in HbA1c of 0.25% (95% CI: 0.18–0.32, I2 = 98.45%, moderate). Waist circumference, BMI (Body Mass Index), SBP (Systolic Blood Pressure), and FPG (fasting plasma glucose) also showed significant deterioration. In the type 2 diabetes setting, weight gain was 2.03 kg (95% CI: 1.63–2.42, I2 = 42.28%, moderate), and HbA1c rose by 0.65% (95% CI: 0.22–1.08, I2 = 96.83%, moderate), while FPG remained stable (0.90 mmol/L; 95% CI: −0.36 to 2.17, I2 = 98.81%, moderate). Subgroup analyses revealed greater weight regain with longer follow-up (>26 weeks: 7.31 kg vs. 2.51 kg) and with semaglutide compared to liraglutide (8.21 kg vs. 4.29 kg). Semaglutide also led to greater increases in waist circumference (3.80 cm vs. 2.69 cm) and SBP (7.09 mmHg vs. 1.56 mmHg). Most outcomes showed no evidence of significant publication bias, with minor asymmetry detected for VLDL (very-low-density lipoprotein) levels in individuals with obesity and for weight change (kg) in patients with type 2 diabetes. The risk of bias assessment using the ROB 2.0 tool rated all included studies as having a low risk. The magnitude and consistency of these effects underscore the physiological consequences of GLP-1RA discontinuation. As the clinical use of GLP-1RAs continues to grow in the management of obesity and diabetes, it is imperative that treatment guidelines address not only initiation and titration but also discontinuation and long-term maintenance strategies to sustain therapeutic gains. This study received no funding.

1 September 2013 in Food Chemistry
Verified
Journal Article
Closed access
YLYi-Ling Lin
Yi-Ling Lin
Yuan-Yen ChangYuan-Yen Chang
Yuan-Yen Chang
DYDeng-Jye Yang
Deng-Jye Yang
BTBor-Show Tzang
Bor-Show Tzang
YCYi-Chen Chen
Yi-Chen Chen

2 May 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SHSheng-Jyun Huang
Sheng-Jyun Huang
TWTzu-Hao Wang
Tzu-Hao Wang
YCYa-Hsuan Chou
Ya-Hsuan Chou
Hui-Min David WangHui-Min David Wang
Hui-Min David Wang
THTSAI-CHING HSU
TSAI-CHING HSU
Wen-Hsuan ChiangWen-Hsuan Chiang
Wen-Hsuan Chiang